The UK Department of Health, after reviewing the performance of the Medicines and Healthcare products Regulatory Agency, has concluded that the agency needs to become more responsive to the needs of its stakeholders1,2.
The review, the DoH says, was carried out as part of the government’s responsibility to ensure that the MHRA is fit for purpose and is operating in the most efficient way3...
Please login to read the full article.
